Latest Healthcare News

Audeara Ltd has reported a landmark FY25 with record cash receipts of $4.9 million, driven by strong domestic sales and expanding global technology partnerships. The company’s strategic R&D and inventory build set the stage for further growth in FY26.

Regis Healthcare has agreed to acquire four premium aged care homes in South-East Queensland from Rockpool, adding 600 beds and boosting its portfolio to 72 homes. The $135 million deal is expected to be earnings accretive in FY26.

Regis Healthcare has agreed to acquire four premium aged care homes in South-East Queensland from Rockpool RAC Holdings, adding 600 beds to its portfolio. The $135 million deal, funded from existing cash reserves, is expected to complete by September 1, 2025.

Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Integral Diagnostics has been served with a legal claim from vendors disputing the earn out valuation of its Imaging Queensland acquisition, despite an independent expert's prior valuation. The company plans to defend the claim, which could have financial and reputational implications.

Austco Healthcare reports robust FY25 growth with revenue climbing over 37% and EBITDA soaring by more than 54%, fueled by strong organic performance and key acquisitions.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.